| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 5,742 | 16,903 | ||
| Short-term investments | 7,970 | 5,420 | ||
| Restricted cash | 0 | 0 | ||
| Accounts receivable | 1,913 | 0 | ||
| Inventories | 0 | 0 | ||
| Other current assets | 2,807 | 2,449 | ||
| Total current assets | 18,432 | 24,772 | ||
| Property and equipment, gross | 551 | - | ||
| Less accumulated depreciation | 404 | - | ||
| Property and equipment, net | 147 | 176 | ||
| Operating lease assets | 10,707 | 11,027 | ||
| Other assets | 881 | 927 | ||
| Total assets | 30,167 | 36,902 | ||
| Accounts payable | 318 | 1,762 | ||
| Accrued compensation | 2,067 | 2,552 | ||
| Accrued research and development expenses | 342 | 971 | ||
| Deferred revenue | 1,011 | 1,607 | ||
| Liability related to the sale of future revenues - current portion | 9,670 | - | ||
| Other current liabilities | 4,649 | 7,671 | ||
| Total current liabilities | 18,057 | 14,563 | ||
| Operating lease liabilities - long-term | 15,005 | 15,426 | ||
| Deferred revenue - long-term | - | 0 | ||
| Liability related to the sale of future revenues - long-term | 31,976 | 40,222 | ||
| Other long-term liabilities | 1,763 | 1,732 | ||
| Total liabilities | 66,801 | 71,943 | ||
| Common stock - 0.0001 par value, 500,000 shares authorized as of september 30, 2025 and december 31, 2024 7,210 and 5,859 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 1 | 1 | ||
| Additional paid-in capital | 1,981,822 | 1,979,114 | ||
| Accumulated other comprehensive income (loss) | 2 | 0 | ||
| Accumulated deficit | -2,018,459 | -2,014,156 | ||
| Total stockholders' equity (deficit) | -36,634 | -35,041 | ||
| Total liabilities and stockholders' equity (deficit) | 30,167 | 36,902 | ||
Atara Biotherapeutics, Inc. (ATRA)
Atara Biotherapeutics, Inc. (ATRA)